Esco Aster
Esco Aster 是一家垂直整合的生物创新风险加速器，提供从创意到退出的端到端合同服务——咨询、研究、CMC 开发、生产、检测、临床开发、战略融资和企业支持；能力可随合作方从早期开发扩展至中试和全面商业化生产。公司由科学家创立，平台服务更广泛的生物基深度科技生物经济——诊断、治疗药物、疫苗、药妆、医学美容、保健食品和细胞农业；其专利制造平台已在多款商业化人用和兽用疫苗、皮肤化妆品以及细胞基营养和临床级干细胞中得到应用……
简介
Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and collaborators translate and scale cell- and cell-derivative technologies “idea-to-exit,” operating two dedicated certified sites for clinical/veterinary/dermocosmetics and for cell-based nutrition/nutricosmetics. Core products/technology center on Tide Motion adherent packed-bed bioreactors (closed automated cell harvesting; linear scale concept noted from 0.1 L to 5,000 L packed-bed volume, and scales up to 55,000 L), plus continuous fermentation and food/cellular agriculture via AsterMavors (complementary proteins). Founded/established in 2015 within Esco Lifesciences Group; spun out as a wholly owned subsidiary in 2018; completed spin-off in 2022 and operates as an affiliate of Esco Lifesciences Group. Headquarters include Singapore (Ayer Rajah Crescent; e.g., #02-01 Blk 67). Scale: the Esco Lifesciences Group is listed as having 1,700 employees and 42 locations (25 countries), but no Esco Aster-specific revenue/capacity/employees figures were provided. Ownership/listing/investors/funding: no stock listing or named investors were given; “Strategic Capital” is described as a fundraising-as-a-service for accredited investors and capital providers, not a disclosed funding round. Key partners/customers named: Shine-On Biomedical (exosome clinical cGMP manufacturing contract); also MOUs with Creative Life Science (Taiwan) and references to collaborations with Institute of Molecular Cell Biology and Bioprocessing Institute. Latest 2025–2026 developments: December 2025 MOU with Creative Life Science; July 2026 CelShaker™ automated cell harvesting system launch; September 2026 interview/feature reporting expansion from CRDMO to broader bioinnovation venture accelerator; and December 12, 2025 exosome manufacturing contract news was dated earlier in the feed. Still active: yes, with news published as late as 2026-09-16.
Sources#
供应的生物解决方案 1
产品与服务
产品: Cell-based cultivated meat; Cell-based chicken paste; Engineered cancer exosomes; Induced Retinal Pigment Epithelium (RPE); BioNOC™ II; CelCradle™; TideXcell™; Tide Motion Platform; GlucCell™; Esco VacciXcell GlucCell™ Glucose Test Strips
认证: ISO 9001:2015; ISO 22000:2018; FSSC 22000; My Green Lab Certification
- 应用
- Human Vaccines · Mesenchymal Stem Cells · Animal Health · Vaccine Production · Biologics and Cell Therapy Production · Cell Therapy · Gene-edited Cell Therapy · Human Vaccines/Oncolytic Viruses · Therapeutic mAbs/Recombinant Protein · Gene Therapy · Food Ingredient/Product Protein · Biomass for Cell-Based Meat Food Formulation
- 认证（官网）
- ISO 9001:2015 · ISO 22000:2018 · FSSC 22000 · My Green Lab Certification
- 客户与合作伙伴
- Nuvonis Technologies GmbH · patients
- 生产基地
- #02-01, Blk 67 Ayer Rajah Crescent, Singapore 139950 — Cells/Viruses/EVs · #02-04 Blk 67 Ayer Rajah Crescent, Singapore 139950 — Clinical Trial Material Operations · #03-20 Blk 71 Ayer Rajah Crescent, Singapore 139951 — Cellular Agriculture and Complementary Proteins (Food) · 36, 20th Road, Taichung Industrial Park, Taichung, 40850 Taiwan — Bioengineering · Semba LS Bldg.4F,3-6-62, Sembahigashi, Minoh-city, Osaka 〒562-0035, Japan — Japan Head Office · LiSH Lab, NORTH 6F, 2-21-1 Takanawa, Minato-ku, Tokyo 〒108-0074, Japan — Takanawa Gateway Lab · Singapore — Vero cell cultivation and vaccine production · Austria — GMP Vero cell line · #02-04 Blk 67 Ayer Rajah Crescent, Singapore 139950 — Esco AsterTide PD-Phase 2 CTM (Cells/Viruses/EVs) · #03-20 Blk 71 Ayer Rajah Crescent, Singapore 139951 — Esco AsterMavors Cellular Agriculture and Complementary Proteins (Food) · #02-01, Blk 67 Ayer Rajah Crescent, Singapore 139950 — Esco Aster Pte. Ltd. · Singapore — Proprietary cell lines, media, other ancillary consumables, and labour
- 产品（官网）
- Cell-based cultivated meat — First company to receive a food processing license from the Singapore Food Authority (SFA) to manufacture cell-based cultivated meat for human consumption. · Cell-based chicken paste — Commenced manufacturing under ISO 22000:2018 certification. · Engineered cancer exosomes — Targeting HLA-G; developing clinical trial drug product with contract testing. · Induced Retinal Pigment Epithelium (RPE) — From pluripotent stem cells for Dry AMD (Age-related Macular Degeneration). · BioNOC™ II — Macrocarriers for Vero cell cultivation. · CelCradle™ — Bioreactor technology for Vero cell cultivation. · TideXcell™ — Automated cell harvesting system for high-density cell culture. · Tide Motion Platform — Platform for localized vaccine production using Vero cells. · GlucCell™ — Device for measuring glucose levels in cell growth assays. · Esco VacciXcell GlucCell™ Glucose Test Strips — Test strips for glucose measurement. · TideMotion® Bioreactors — Platform for scalable culture of adherent cells. · CelCradle™ Bioreactor — Used in the production of viral vectors.
- 研发设施
- Austria
摘自公司官网: about · products · production · quality · rnd · contact · sustainability · topic
新闻与状态 6
- 2026-09 最新状态: 2026年9月，Esco Aster 宣布在既有 CRDMO 基础上升级为更广泛的生物创新风险加速器。 ↗ ↗ ↗
- 2026-09-16 News & Events | Esco AsterEsco Aster is expanding from its CRDMO foundation into broader BioInnovation ventures, highlighting growth into automated cell harvesting (CelShaker) and expanded bioprocessing/manufacturing capabilities, including partnerships and cGMP-focused projects in …
- 2026-07-24 Bioengineering Launches CelShaker™, an Automated Cell Harvesting System for GMP Cell Manufacturing | Esco AsterEsco Aster is expanding its end-to-end bioprocessing capabilities by launching the CelShaker™, an automated cell-harvesting system designed to integrate with its BelloStage and CelCradle platforms for standardized, scalable GMP manufacturing of adherent cells …
- 2026-09-17 ESCO ASTER PTE LTD built one core technology, a patented bioreactor, and it now powers vaccines, cell therapies, and even cell-based food.Esco Aster Pte Ltd has developed a patented bioreactor core technology that powers vaccines, cell therapies, and cell-based food, making them the world’s first certified seller of cell-based foods and launching Metamorphosis, an equity-free biotech accelerator …
- 2026-07-16 Advancing the Future of Extracellular Vesicle Therapeutics at EVANTICA 2026Esco Aster participated in EVANTICA 2026 to showcase end-to-end EV/exosome development and cGMP manufacturing capabilities, highlight XL Lin’s talk on “cGMP Exosomes for Targeting Cancer,” and engage with researchers and industry partners to advance …
- 2026-09-08 And just like that… ISCT Asia 2026 is a wrap!Esco Aster showcased its CRDMO capabilities and Tide Motion bioreactor platform at ISCT Asia 2026, highlighting scalable, closed automated bioprocessing and cell harvesting. They emphasized collaboration with Oncofibro and future engagement with the CGT …
- 2026-08-07 Esco Aster is Heading to ISCT Asia 2026! | ESCO ASTER PTE LTDEsco Aster is showcasing its cell and gene therapy capabilities at ISCT Asia 2026, highlighting scalable bioprocessing for iPSC/MSC manufacturing, a fixed packed-bed bioreactor, and automated harvesting, while promoting collaboration opportunities and …
关系网络：股东、合作伙伴、同类
股权与投资方 1
| 母公司 | Esco Lifesciences Group |
同类企业
ScaleUp Bio · Cell AgriTech · Laurus Bio · ULTIMEAT · Shiok Meats · IntegriCulture inc.（インテグリカルチャー株式会社） · Provis Biolabs · CellX
身份与联系方式
联系方式、人员和法律信息仅向会员开放。
会员登录